Shucai Zhang

Capital Medical University - Department of Oncology

Beijing

China

SCHOLARLY PAPERS

1

DOWNLOADS

221

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Furmonertinib (AST2818) Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multi-Center, Double-Blind, Randomized Phase 3 Study (FURLONG)

Number of pages: 53 Posted: 10 Jan 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Harbin Medical University - Department of Medical Oncology, Xuzhou Central Hospital - Department of Medical Oncology, China Medical University - Department of Medical Oncology, Zhengzhou University - Henan Provincial People's Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Medical Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Xuzhou Medical College - Department of Respiratory Medicine, Nantong Tumor Hospital - Department of Medical Oncology, Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine, Dalian University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Respiratory Medicine, Jilin Cancer Hospital - Department of Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Capital Medical University - Department of Oncology, Hebei University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Nantong University - Department of Respiratory Medicine, Shanghai Allist Pharmaceutical Technology, Shanghai Allist Pharmaceutical Technology and Shanghai Allist Pharmaceutical Technology
Downloads 221 (295,280)

Abstract:

Loading...

Furmonertinib, AST2818, NSCLC, EGFR, TKI